Alcami, a contract development and manufacturing organization for active pharmaceutical ingredients (APIs) and drug products, has finalized manufacturing and quality agreements with Solasia Pharma, a Tokyo-based specialty pharmaceutical company, for the clinical supply manufacture of the API, darinaparsin, a mitochondrial-targeted agent developed for treating various hematologic and solid cancers.

In March 2011, Solasia acquired the rights to darinaparsin from Ziopharm Oncology, a biopharmaceutical company, for treating peripheral T-cell lymphoma. The agent is currently in Phase II trials in Asia.

Process development for darinaparsin and clinical manufacturing will begin within Alcami’s new highly potent API suites in the fourth quarter of 2017, located at its API Center of Excellence in Germantown, Wisconsin. 

Source: Alcami